Company
Virbac SA
Headquarters: Carros, France
Employees: 4,907
CEO: Mr. Habib Ramdani
Market Cap
€2.58 Billion
EUR as of Jan. 1, 2025
US$2.68 Billion
Virbac SA Categories
France Healthcare Drug Manufacturers—GeneralFrance Healthcare France Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
| Merck | $244.44 B |
| Roche | $219.35 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Virbac SA manufactures and sells pharmaceutical, biological, nutritional, and diagnostic products for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, and the Middle East and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | €1.34 B |
| EBITDA | €226.7 M |
| Gross Profit TTM | €892.8 M |
| Profit Margin | 10.52% |
| Operating Margin | 21.20% |
| Quarterly Revenue Growth | 15.10% |
Stocks & Indices
Virbac SA has the following listings and related stock indices.
Stock: Euronext: VIRP wb_incandescent
Stock: FSX: V16 wb_incandescent
Stock: OTC: VRBCF wb_incandescent